Brachytherapy Devices Market by Product Type (High Dose Rate, Low Dose Rate, Pulsed Dose Rate), Source Type (Cs-137, I-125, Ir-192), Application, End User - Global Forecast 2025-2032
Description
The Brachytherapy Devices Market was valued at USD 1.41 billion in 2024 and is projected to grow to USD 1.60 billion in 2025, with a CAGR of 13.99%, reaching USD 4.03 billion by 2032.
Comprehensive introduction to brachytherapy devices, clinical role, evolving technologies and strategic importance within multidisciplinary oncologic care
Brachytherapy devices occupy a distinct and enduring role within oncologic care by delivering localized radiotherapy with high conformality to tumors while sparing surrounding healthy tissue. These systems encompass a spectrum of delivery platforms and applicators used across diverse clinical workflows, and they integrate radiopharmaceutical sources, remote afterloaders, and increasingly sophisticated imaging and planning capabilities. Clinicians rely on brachytherapy to achieve durable local control for a range of indications where precision and dose fall-off drive clinical benefit, and teams continuously adapt procedural approaches to accommodate patient preference, anatomical complexity, and evolving standards of care.
As treatment paradigms evolve, so do the device and service models that support brachytherapy. Innovations in image guidance, applicator design, and treatment planning software are expanding the clinical envelope for this modality. Concurrently, operational pressures - including supply chain resilience for source materials, procedural throughput, and outpatient delivery - are reshaping how providers evaluate device selection and capital investment. Therefore, a clear understanding of technology characteristics, clinical integration requirements, and operational trade-offs is essential for hospital administrators, clinical leaders, and device manufacturers seeking to align product development and adoption strategies with contemporary therapeutic priorities.
Analysis of transformative shifts reshaping the brachytherapy landscape including imaging, planning, isotope management, outpatient care and digital precision
The brachytherapy landscape is undergoing transformative shifts driven by a convergence of clinical, technological, and operational forces. Image-guided brachytherapy and advanced treatment planning systems are improving target delineation and dose conformity, which in turn supports more conservative treatment approaches and enables broader use across patient populations. In parallel, novel applicator designs and single-use components are reducing procedural complexity and infection risk, while additive manufacturing is permitting rapid prototyping of patient-specific applicators that match anatomic variations with greater precision.
Moreover, there is growing emphasis on outpatient and ambulatory delivery models that reduce inpatient resource utilization and improve patient convenience. As a result, device developers are prioritizing portability, streamlined workflows, and compatibility with lower-footprint procedural settings. At the same time, digital tools - including machine learning algorithms for planning optimization and software modules for seed tracking and quality assurance - are increasingly embedded in the treatment pathway, enhancing reproducibility and enabling tighter integration with hospital information systems. Taken together, these shifts are not only improving clinical performance but are also reshaping procurement criteria, training requirements, and support services across the ecosystem.
Assessment of cumulative impacts of United States tariff actions in 2025 on device supply chains, isotope sourcing and cross-border regulatory change
Tariff actions implemented by the United States in 2025 introduce layered challenges across device manufacturing, component sourcing, and the movement of radiopharmaceuticals that underpin brachytherapy practice. Import duties on precision-machined parts, electronics, and specialized medical-grade materials increase landed costs for manufacturers that rely on globalized supply chains. Consequently, procurement teams must reassess vendor contracts and total landed cost calculations, while manufacturers may reconfigure supplier networks to mitigate exposure to tariff volatility. In turn, providers that depend on consistent instrument availability face potential disruptions to capital acquisition schedules and spare-part inventories, which could lengthen equipment downtime unless contingency stocks and alternative suppliers are identified.
Furthermore, tariffs affecting cross-border transport of isotopes and sealed sources can complicate logistics for source replacement and inventory management. Given the time-sensitive nature of some radioisotopes, any incremental customs clearance timelines or added administrative burdens can stress clinical scheduling and resource allocation. To manage these pressures, stakeholders are strengthening customs compliance capabilities, expanding redundant supply options, and exploring onshoring or near-shoring strategies where feasible. In addition, regulators and procurement authorities are likely to intensify scrutiny of supply continuity plans, prompting closer collaboration between device makers, isotope producers, and clinical networks to maintain uninterrupted patient care pathways.
Key segmentation insights across product types, clinical applications, source categories and end-user settings shaping technology adoption and care pathways
Insights derived from product, application, source and end-user segmentation reveal differentiated adoption patterns and operational imperatives across the brachytherapy ecosystem. Based on product type, systems that deliver High Dose Rate treatments emphasize remote afterloading, rapid procedural throughput and integrated planning software, while Low Dose Rate platforms continue to support seed implantation workflows that prioritize permanence and outpatient suitability; Pulsed Dose Rate solutions occupy a hybrid space for clinicians balancing pulsed fractionation with radiobiological considerations. Transitioning to clinical application, devices used in breast cancer procedures demand applicator conformity and cosmesis-sensitive ergonomics, cervical cancer workflows require intracavitary adaptability and robust imaging integration, ocular tumor applications focus on extreme localization and source miniaturization, and prostate cancer treatments prioritize precise seed placement and real-time verification.
Turning to source type, sealed isotopes such as Cs-137, I-125, Ir-192 and Pd-103 each bring distinct handling, half-life and shielding considerations that influence inventory cadence and safety protocols. Finally, end-user settings shape procurement and operational choices: Ambulatory Surgical Centres prioritize compact systems with rapid turnover and simplified maintenance; Cancer Research Centers value modular platforms and flexible source options to support investigational protocols; and Hospitals require enterprise-grade integration, serviceability and compliance workflows to support complex multidisciplinary cases. Understanding how these segmentation axes intersect helps stakeholders tailor device design, service models and training programs to real-world care environments.
Regional intelligence highlighting deployment, innovation, reimbursement and supply resilience across the Americas, Europe Middle East & Africa and Asia-Pacific
Regional dynamics are shaping distinct adoption curves, regulatory landscapes and supply chain strategies across global geographies. In the Americas, high-volume cancer centers and established radiation oncology networks drive sophisticated integration of image guidance and high throughput HDR workflows, while reimbursement structures and hospital consolidation influence procurement cycles and the prioritization of outpatient-capable devices. Conversely, Europe, Middle East & Africa present a heterogeneous regulatory and reimbursement map, where high-income countries lead in clinical trial activity and technology uptake, and other jurisdictions prioritize cost-effective, robust devices and local training to expand access to brachytherapy services.
Asia-Pacific demonstrates rapidly expanding clinical capacity, with investments in cancer infrastructure, increasing numbers of trained brachytherapy practitioners, and localized manufacturing partnerships that reduce reliance on distant supply chains. Across all regions, supply resilience and isotopic logistics remain central concerns; therefore, stakeholders are adapting by fostering regional distribution hubs, negotiating multi-supplier agreements, and aligning with local regulatory authorities to streamline import and handling processes. These regional variations necessitate tailored commercialization, clinical training and post-market support strategies to ensure devices meet the practical needs of each healthcare environment.
Strategic company-level insights into competitive behavior, innovation pipelines, partnership models and operational resilience shaping device development
Company-level behavior in the brachytherapy domain reflects a balance between incremental innovation, strategic partnerships, and operational resilience. Leading manufacturers are allocating resources to improve software-driven planning tools, expand applicator portfolios, and refine usability features that shorten procedure times. At the same time, newer entrants and specialized medtech firms are introducing niche innovations such as customizable applicators, advanced dosimetry modules, and integrated digital quality assurance, which together stimulate competitive differentiation and broaden clinical options.
Partnership models are increasingly collaborative, with device developers aligning with radiopharmaceutical suppliers, imaging vendors, and clinical research networks to deliver bundled solutions and evidence-generation programs. Operationally, companies are investing in service networks, remote diagnostics and training curricula to support decentralized delivery settings and reduce lifecycle costs for end users. These strategic moves reflect an industry-wide recognition that product performance must be matched by reliable support services, supply continuity, and robust clinical evidence to secure durable adoption in complex care pathways.
Recommendations for industry leaders to fortify supply chains, enable clinical adoption, refine regulatory approaches and center devices on patient outcomes
Industry leaders should take deliberate actions to strengthen supply resilience, deepen clinical integration, and accelerate value realization for providers and patients. First, diversifying supplier networks and building regional inventory buffers will mitigate exposure to tariff shocks and logistics disruptions while improving uptime for critical devices. Second, investing in interoperable software and workflow simplification helps accelerate clinical adoption by reducing training burdens and enabling smoother integration with existing hospital systems. Third, prioritizing clinical evidence generation - including prospective observational studies and pragmatic clinical protocols - will support clinician confidence and inform payer discussions about procedural value.
Moreover, organizations should explore modular product architectures that permit phased upgrades and retrofit capabilities, reducing capital friction for purchasers. Engaging early with regulatory bodies to clarify compliance pathways and to harmonize safety standards across jurisdictions will expedite market entry and post-market surveillance. Finally, centering design on patient experience and outpatient feasibility will open new care pathways and improve uptake among providers seeking low-footprint solutions, thereby aligning commercial objectives with improved patient outcomes.
Rigorous research methodology detailing data sources, expert interviews, clinical evidence synthesis and triangulation used to validate device and clinical insights
The research approach combined systematic literature review, structured expert interviews, clinical protocol analysis and regulatory document mapping to ensure robust and validated conclusions. Peer-reviewed clinical publications, technical device white papers, professional society guidelines and regulatory filings provided the foundational evidence base, while interviews with practicing radiation oncologists, medical physicists, supply chain managers and device engineers supplied contextual insights and operational nuance. Data triangulation ensured that qualitative inputs were cross-checked against published clinical outcomes and procedural standards, and methodological transparency was preserved through documented interview guides and a reproducible evidence-log.
Wherever possible, findings were corroborated using multiple independent sources, and limitations were explicitly acknowledged when evidence was sparse or evolving. Ethical considerations guided expert engagements, and confidentiality safeguards protected proprietary information shared by participants. This combined qualitative and documentary approach yields actionable insights while preserving analytic rigor and relevance for both clinical and commercial stakeholders.
Conclusion synthesizing strategic opportunities, operational challenges and priority actions to guide leadership decisions in brachytherapy deployment
In conclusion, brachytherapy devices remain a cornerstone of precision radiation therapy, supported by a wave of technological enhancements and shifting delivery models. Opportunities lie in device designs that support outpatient workflows, enhanced imaging and planning integration, and resilient supply chains that can withstand geopolitical and commercial disruptions. At the same time, clinical adoption depends on streamlined workflows, demonstrable clinical value, and reliable post-sale support that reduce implementation friction for providers.
Therefore, aligning product development with real-world procedural needs, investing in collaborative partnerships that span isotopes to imaging, and proactively managing regulatory and supply chain complexity will position organizations to translate technical innovation into measurable clinical and operational impact. Continued diligence in evidence generation and stakeholder alignment will be essential to capitalize on the modality’s unique therapeutic advantages while responding to evolving external pressures.
Note: PDF & Excel + Online Access - 1 Year
Comprehensive introduction to brachytherapy devices, clinical role, evolving technologies and strategic importance within multidisciplinary oncologic care
Brachytherapy devices occupy a distinct and enduring role within oncologic care by delivering localized radiotherapy with high conformality to tumors while sparing surrounding healthy tissue. These systems encompass a spectrum of delivery platforms and applicators used across diverse clinical workflows, and they integrate radiopharmaceutical sources, remote afterloaders, and increasingly sophisticated imaging and planning capabilities. Clinicians rely on brachytherapy to achieve durable local control for a range of indications where precision and dose fall-off drive clinical benefit, and teams continuously adapt procedural approaches to accommodate patient preference, anatomical complexity, and evolving standards of care.
As treatment paradigms evolve, so do the device and service models that support brachytherapy. Innovations in image guidance, applicator design, and treatment planning software are expanding the clinical envelope for this modality. Concurrently, operational pressures - including supply chain resilience for source materials, procedural throughput, and outpatient delivery - are reshaping how providers evaluate device selection and capital investment. Therefore, a clear understanding of technology characteristics, clinical integration requirements, and operational trade-offs is essential for hospital administrators, clinical leaders, and device manufacturers seeking to align product development and adoption strategies with contemporary therapeutic priorities.
Analysis of transformative shifts reshaping the brachytherapy landscape including imaging, planning, isotope management, outpatient care and digital precision
The brachytherapy landscape is undergoing transformative shifts driven by a convergence of clinical, technological, and operational forces. Image-guided brachytherapy and advanced treatment planning systems are improving target delineation and dose conformity, which in turn supports more conservative treatment approaches and enables broader use across patient populations. In parallel, novel applicator designs and single-use components are reducing procedural complexity and infection risk, while additive manufacturing is permitting rapid prototyping of patient-specific applicators that match anatomic variations with greater precision.
Moreover, there is growing emphasis on outpatient and ambulatory delivery models that reduce inpatient resource utilization and improve patient convenience. As a result, device developers are prioritizing portability, streamlined workflows, and compatibility with lower-footprint procedural settings. At the same time, digital tools - including machine learning algorithms for planning optimization and software modules for seed tracking and quality assurance - are increasingly embedded in the treatment pathway, enhancing reproducibility and enabling tighter integration with hospital information systems. Taken together, these shifts are not only improving clinical performance but are also reshaping procurement criteria, training requirements, and support services across the ecosystem.
Assessment of cumulative impacts of United States tariff actions in 2025 on device supply chains, isotope sourcing and cross-border regulatory change
Tariff actions implemented by the United States in 2025 introduce layered challenges across device manufacturing, component sourcing, and the movement of radiopharmaceuticals that underpin brachytherapy practice. Import duties on precision-machined parts, electronics, and specialized medical-grade materials increase landed costs for manufacturers that rely on globalized supply chains. Consequently, procurement teams must reassess vendor contracts and total landed cost calculations, while manufacturers may reconfigure supplier networks to mitigate exposure to tariff volatility. In turn, providers that depend on consistent instrument availability face potential disruptions to capital acquisition schedules and spare-part inventories, which could lengthen equipment downtime unless contingency stocks and alternative suppliers are identified.
Furthermore, tariffs affecting cross-border transport of isotopes and sealed sources can complicate logistics for source replacement and inventory management. Given the time-sensitive nature of some radioisotopes, any incremental customs clearance timelines or added administrative burdens can stress clinical scheduling and resource allocation. To manage these pressures, stakeholders are strengthening customs compliance capabilities, expanding redundant supply options, and exploring onshoring or near-shoring strategies where feasible. In addition, regulators and procurement authorities are likely to intensify scrutiny of supply continuity plans, prompting closer collaboration between device makers, isotope producers, and clinical networks to maintain uninterrupted patient care pathways.
Key segmentation insights across product types, clinical applications, source categories and end-user settings shaping technology adoption and care pathways
Insights derived from product, application, source and end-user segmentation reveal differentiated adoption patterns and operational imperatives across the brachytherapy ecosystem. Based on product type, systems that deliver High Dose Rate treatments emphasize remote afterloading, rapid procedural throughput and integrated planning software, while Low Dose Rate platforms continue to support seed implantation workflows that prioritize permanence and outpatient suitability; Pulsed Dose Rate solutions occupy a hybrid space for clinicians balancing pulsed fractionation with radiobiological considerations. Transitioning to clinical application, devices used in breast cancer procedures demand applicator conformity and cosmesis-sensitive ergonomics, cervical cancer workflows require intracavitary adaptability and robust imaging integration, ocular tumor applications focus on extreme localization and source miniaturization, and prostate cancer treatments prioritize precise seed placement and real-time verification.
Turning to source type, sealed isotopes such as Cs-137, I-125, Ir-192 and Pd-103 each bring distinct handling, half-life and shielding considerations that influence inventory cadence and safety protocols. Finally, end-user settings shape procurement and operational choices: Ambulatory Surgical Centres prioritize compact systems with rapid turnover and simplified maintenance; Cancer Research Centers value modular platforms and flexible source options to support investigational protocols; and Hospitals require enterprise-grade integration, serviceability and compliance workflows to support complex multidisciplinary cases. Understanding how these segmentation axes intersect helps stakeholders tailor device design, service models and training programs to real-world care environments.
Regional intelligence highlighting deployment, innovation, reimbursement and supply resilience across the Americas, Europe Middle East & Africa and Asia-Pacific
Regional dynamics are shaping distinct adoption curves, regulatory landscapes and supply chain strategies across global geographies. In the Americas, high-volume cancer centers and established radiation oncology networks drive sophisticated integration of image guidance and high throughput HDR workflows, while reimbursement structures and hospital consolidation influence procurement cycles and the prioritization of outpatient-capable devices. Conversely, Europe, Middle East & Africa present a heterogeneous regulatory and reimbursement map, where high-income countries lead in clinical trial activity and technology uptake, and other jurisdictions prioritize cost-effective, robust devices and local training to expand access to brachytherapy services.
Asia-Pacific demonstrates rapidly expanding clinical capacity, with investments in cancer infrastructure, increasing numbers of trained brachytherapy practitioners, and localized manufacturing partnerships that reduce reliance on distant supply chains. Across all regions, supply resilience and isotopic logistics remain central concerns; therefore, stakeholders are adapting by fostering regional distribution hubs, negotiating multi-supplier agreements, and aligning with local regulatory authorities to streamline import and handling processes. These regional variations necessitate tailored commercialization, clinical training and post-market support strategies to ensure devices meet the practical needs of each healthcare environment.
Strategic company-level insights into competitive behavior, innovation pipelines, partnership models and operational resilience shaping device development
Company-level behavior in the brachytherapy domain reflects a balance between incremental innovation, strategic partnerships, and operational resilience. Leading manufacturers are allocating resources to improve software-driven planning tools, expand applicator portfolios, and refine usability features that shorten procedure times. At the same time, newer entrants and specialized medtech firms are introducing niche innovations such as customizable applicators, advanced dosimetry modules, and integrated digital quality assurance, which together stimulate competitive differentiation and broaden clinical options.
Partnership models are increasingly collaborative, with device developers aligning with radiopharmaceutical suppliers, imaging vendors, and clinical research networks to deliver bundled solutions and evidence-generation programs. Operationally, companies are investing in service networks, remote diagnostics and training curricula to support decentralized delivery settings and reduce lifecycle costs for end users. These strategic moves reflect an industry-wide recognition that product performance must be matched by reliable support services, supply continuity, and robust clinical evidence to secure durable adoption in complex care pathways.
Recommendations for industry leaders to fortify supply chains, enable clinical adoption, refine regulatory approaches and center devices on patient outcomes
Industry leaders should take deliberate actions to strengthen supply resilience, deepen clinical integration, and accelerate value realization for providers and patients. First, diversifying supplier networks and building regional inventory buffers will mitigate exposure to tariff shocks and logistics disruptions while improving uptime for critical devices. Second, investing in interoperable software and workflow simplification helps accelerate clinical adoption by reducing training burdens and enabling smoother integration with existing hospital systems. Third, prioritizing clinical evidence generation - including prospective observational studies and pragmatic clinical protocols - will support clinician confidence and inform payer discussions about procedural value.
Moreover, organizations should explore modular product architectures that permit phased upgrades and retrofit capabilities, reducing capital friction for purchasers. Engaging early with regulatory bodies to clarify compliance pathways and to harmonize safety standards across jurisdictions will expedite market entry and post-market surveillance. Finally, centering design on patient experience and outpatient feasibility will open new care pathways and improve uptake among providers seeking low-footprint solutions, thereby aligning commercial objectives with improved patient outcomes.
Rigorous research methodology detailing data sources, expert interviews, clinical evidence synthesis and triangulation used to validate device and clinical insights
The research approach combined systematic literature review, structured expert interviews, clinical protocol analysis and regulatory document mapping to ensure robust and validated conclusions. Peer-reviewed clinical publications, technical device white papers, professional society guidelines and regulatory filings provided the foundational evidence base, while interviews with practicing radiation oncologists, medical physicists, supply chain managers and device engineers supplied contextual insights and operational nuance. Data triangulation ensured that qualitative inputs were cross-checked against published clinical outcomes and procedural standards, and methodological transparency was preserved through documented interview guides and a reproducible evidence-log.
Wherever possible, findings were corroborated using multiple independent sources, and limitations were explicitly acknowledged when evidence was sparse or evolving. Ethical considerations guided expert engagements, and confidentiality safeguards protected proprietary information shared by participants. This combined qualitative and documentary approach yields actionable insights while preserving analytic rigor and relevance for both clinical and commercial stakeholders.
Conclusion synthesizing strategic opportunities, operational challenges and priority actions to guide leadership decisions in brachytherapy deployment
In conclusion, brachytherapy devices remain a cornerstone of precision radiation therapy, supported by a wave of technological enhancements and shifting delivery models. Opportunities lie in device designs that support outpatient workflows, enhanced imaging and planning integration, and resilient supply chains that can withstand geopolitical and commercial disruptions. At the same time, clinical adoption depends on streamlined workflows, demonstrable clinical value, and reliable post-sale support that reduce implementation friction for providers.
Therefore, aligning product development with real-world procedural needs, investing in collaborative partnerships that span isotopes to imaging, and proactively managing regulatory and supply chain complexity will position organizations to translate technical innovation into measurable clinical and operational impact. Continued diligence in evidence generation and stakeholder alignment will be essential to capitalize on the modality’s unique therapeutic advantages while responding to evolving external pressures.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
196 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Integration of MRI and ultrasound real-time imaging for adaptive brachytherapy treatment planning and delivery
- 5.2. Adoption of 3D-printed patient-specific brachytherapy applicators to improve dose conformity and reduce setup time
- 5.3. Development of novel low-dose-rate isotopes like cesium-131 for faster radiation decay and improved patient outcomes
- 5.4. Introduction of compact high-dose-rate afterloaders enabling outpatient brachytherapy and reduced hospital stays
- 5.5. Emergence of AI-driven treatment planning software for precise seed placement and reduced procedural risks
- 5.6. Expansion of MR-guided brachytherapy adoption in emerging markets driven by favorable reimbursement policies
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Brachytherapy Devices Market, by Product Type
- 8.1. High Dose Rate
- 8.2. Low Dose Rate
- 8.3. Pulsed Dose Rate
- 9. Brachytherapy Devices Market, by Source Type
- 9.1. Cs-137
- 9.2. I-125
- 9.3. Ir-192
- 9.4. Pd-103
- 10. Brachytherapy Devices Market, by Application
- 10.1. Breast Cancer
- 10.2. Cervical Cancer
- 10.3. Ocular Tumors
- 10.4. Prostate Cancer
- 11. Brachytherapy Devices Market, by End User
- 11.1. Ambulatory Surgical Centres
- 11.2. Cancer Research Centers
- 11.3. Hospitals
- 12. Brachytherapy Devices Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Brachytherapy Devices Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Brachytherapy Devices Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. Becton, Dickinson and Company
- 15.3.2. Biobot Surgical Pte Ltd.
- 15.3.3. Boston Scientific Corporation
- 15.3.4. C4 Imaging LLC
- 15.3.5. Carl Zeiss AG
- 15.3.6. CivaTech Oncology
- 15.3.7. Dexur Inc.
- 15.3.8. Eckert & Ziegler BEBIG S.A.
- 15.3.9. Elekta AB
- 15.3.10. General Electric Company
- 15.3.11. Guangzhou Perception Vision Medical Technologies Co.,Ltd.
- 15.3.12. Hologic Inc.
- 15.3.13. iCAD, Inc.
- 15.3.14. IsoAid, LLC
- 15.3.15. Merit Medical Systems, Inc.
- 15.3.16. Mick Radio-Nuclear Instruments Inc.
- 15.3.17. Panacea Medical Technologies Pvt. Ltd.
- 15.3.18. Perspective Therapeutics
- 15.3.19. Qfix
- 15.3.20. SeeDOS Ltd.
- 15.3.21. Siemens Healthineers AG
- 15.3.22. Sun Nuclear Corporation
- 15.3.23. Theragenics Corporation
- 15.3.24. Valco Instruments Company Incorporated
- 15.3.25. Varian Medical Systems Inc.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
